Targanta Therapeutics Corp., the latest local biotech company to go public this year, had an underwhelming debut yesterday. First, the Cambridge company was forced to price its initial shares at $10, well below the $12 to $14 range expected. Then, during the first day of trading, shares slipped another 60 cents to $9.40, down 6 percent.
